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S U M M A R Y
Globalization has increased both the number of emergent diseases and the diversity of co-infections,
which could in turn mutually inﬂuence the pathogenesis of well-known infectious diseases. Here, we
report the ﬁrst series of chronic human T-cell lymphotropic virus type 1 (HTLV-1) patients co-infected
with the dengue fever virus. As both of these diseases are immuno-mediated, we anticipated
interference in the development of both diseases, with atypical clinical and laboratory parameter results.
All the patients had classic dengue fever, and the main outstanding abnormality was leukopenia
associated with lymphopenia. Although a mutual inﬂuence was expected, dengue fever did not affect the
clinical course of HTLV-1 infection, and HTLV-1 proviral loads revealed unpredictable patterns of change.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Human T-cell lymphotropic virus type 1 (HTLV-1) is the
etiologic agent of a slowly progressive neurodegenerative disease
named HTLV-1-associated myelopathy/tropical spastic parapar-
esis (HAM/TSP), and infects mainly CD4+ T-cells. In HAM/TSP
patients, activated T-cells migrate into the central nervous system
after blood–brain barrier breakdown induced by proinﬂammatory
cytokines,1 which are also involved in tissue damage related to
disease development.2,3 It has also been claimed that dengue fever
is an immunopathological disease, with patients initially present-
ing fever, retro-orbital headache, severe myalgia, and rash.4
Thereafter, some individuals can rapidly develop dengue hemor-
rhagic fever, which is characterized by thrombocytopenia, diffuse
capillary leakage, hemoconcentration, and hypotension, which
may be followed by hemorrhage. Monocytes/macrophages are
considered target cells for dengue infection, acting as antigen-
presenting cells and secrete cytokines that participate in T-cell
activation5 and in the control of endothelium permeability.6
Therefore, the pathophysiological mechanisms observed in HTLV-1
infection and dengue fever could induce clinical and laboratory* Corresponding author. Tel.: +55 21 3865 9654.
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proviral load (PVL), which is associated with HAM/TSP progres-
sion,7 and/or more severe clinical manifestations of dengue fever.
The impact of pathogens, such as hepatitis C virus8 and
Strongyloides stercoralis,9 on the evolution of HTLV-associated
diseases has been subject of studies. Pathogen–host interactions in
co-infected individuals have been reported to be associated with a
dysfunctional cell immune response and disease severity.
The Instituto de Pesquisa Clı´nica Evandro Chagas/Fundac¸a˜o
Oswaldo Cruz (IPEC/FIOCRUZ) is a reference center for acute febrile
diseases and neuroinfections, particularly HTLV-1 infection, with a
cohort of 505 patients. In view of the paucity of data in the medical
literature concerning co-infections in patients with HTLV-1, we
describe here the main clinical and laboratory manifestations of
this series of cases.
2. Methods
During the 2011 dengue epidemic in Rio de Janeiro, Brazil,
characterized by circulation of the four dengue virus (DENV)
serotypes with predominance of serotype 1, four HTLV-1-infected
patients followed in the IPEC/FIOCRUZ cohort were admitted with
a suspicion of dengue infection. Peripheral blood samples from all
patients were submitted to reverse transcription PCR (RT-PCR) for
the detection and typing of DENV10 and screening of DENV-speciﬁcses. Published by Elsevier Ltd. All rights reserved.
Table 1
Dengue fever in HTLV-1 patients: main clinical and laboratory data
Age
(years)
Gender Dengue
classiﬁcation
HTLV-1-associated
disease
EDSS
progression
Lower leukocyte
count ( 109/l)
Platelet count
( 109/l)
HTLV PVL
before DF (%)
HTLV PVL
after DF (%)
Case 1a 50 M DF AC No 2.30 76 ND ND
Case 2 60 F DF HAM/TSP No 1.92 188 11.01 16.32
Case 3 49 M DF Polymyositis No 2.91 201 4.64 4.73
Case 4 56 F DF HAM/TSP No 3.11 161 5.12 3.10
AC, asymptomatic carrier; DF, dengue fever; EDSS, Expanded Disability Status Scale; F, female; HAM/TSP, HTLV-1-associated myelopathy/tropical spastic paraparesis; HTLV-
1, human T-cell lymphotropic virus type 1; M, male; ND, not detectable (<1 infected cell in 104 peripheral blood leukocytes); PVL, proviral load.
a HIV co-infected.
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Australia). Clinical and laboratory data are summarized in
Table 1, and include: leukocyte and platelet counts, HTLV-1 PVL
measured as a percentage of infected cells in peripheral blood
leukocytes (PBL) before and after dengue fever, and score on the
Expanded Disability Status Scale (EDSS)11 employed to evaluate
the clinical progression of HAM/TSP. Written informed consent
was obtained from the patients for publication of this case series
report.
3. Results and case reports
All patients were positive for the presence of DENV-speciﬁc IgM
and for DENV-1 by RT-PCR (except case 4). There was no evidence
of hemoconcentration or bleeding, and the serum albumin levels
remained normal in all cases. The four patients presented classic
dengue fever, accompanied by leukopenia, and the EDSS score
remained unaltered even though the four patients had different
clinical manifestations of HTLV-1 infection (Table 1).
3.1. Case 1
A 50-year-old man was admitted to the hospital with fever,
headache, and retro-orbital pain. He had leukopenia with
lymphocytosis and thrombocytopenia (platelet count 76  109/
l), and was hospitalized for 4 days because of neutropenia (cell
count 1.54  109/l). This patient was HIV co-infected but
asymptomatic for both retroviral infections. Before the onset of
dengue fever, his CD4 cell count was higher than 1000 cells/mm3;
His HIV viral load (VL) was below 50 copies/mm3, and HTLV-1 PVL
was undetectable. During and after dengue fever, his clinical
condition in association with the HTLV-1 and HIV infections
remained unaltered. After dengue fever, he maintained high levels
of CD4 lymphocytes (939 cells/mm3), and HTLV-1 PVL and HIV VL
both remained undetectable.
3.2. Case 2
A 60-year-old woman was admitted with fever, headache, retro-
orbital pain, prostration, myalgia, arthralgia, and vomiting that
began the day before admission. Her total leukocyte count decreased
from 6.3  109/l (day 2) to 1.92  109/l (day 4), but the platelet
counts remained normal. This patient had a HAM/TSP EDSS score of
7, which remained unaltered. Nevertheless, the PVL increased
48.22% (from 11.01% to 16.32% infected cells/PBL) (Table 1).
3.3. Case 3
A 49-year-old man was admitted with fever, myalgia, and
headache. His total leukocyte count decreased from 4.88 to
2.91  109/l, and platelet counts remained normal. This patient
had HTLV-1-related polymyositis with an EDSS score of 0, which
remained unaltered. His HTLV-1 PVL was also unaltered (4.64% to
4.73% infected cells/PBL) (Table 1).3.4. Case 4
A 56-year-old woman was admitted with fever, headache,
retro-orbital pain, and myalgia. She had leukopenia (3.11  109/
l), but no thrombocytopenia (Table 1). DENV RT-PCR was not
performed because blood was collected more than 5 days after
disease onset. This patient had HAM/TSP (EDSS score 7) and
there were no changes in her neurological condition. Her HTLV-1
PVL decreased 39.5% (from 5.12% to 3.10% infected cells/PBL)
(Table 1).
4. Discussion
Despite the small number of cases, this is the ﬁrst report of
dengue fever and HTLV-1 co-infection. The occurrence of
dengue fever in HTLV-1 patients could hypothetically inﬂuence
pathophysiological mechanisms and induce distinct manifes-
tations in the course of HTLV-1 infection. HTLV-1 infects
lymphocytes,7 which are initially depleted during dengue virus
infection.12,13 On the other hand, monocytes/macrophages
infected by DENV secrete proinﬂammatory cytokines that
enhance T-cell activation and alter endothelium permeability,6
which could inﬂuence T-cell migration into the central nervous
system leading to HAM/TSP progression. The inﬂuence of other
pathogens on HTLV-1 patient clinical and laboratory proﬁles
can be observed in co-infections, such as Strongyloides
stercoralis9 and hepatitis C virus.8
However, in this case series, it was observed that this co-
infection did not alter the clinical course of either HTLV-1 or
dengue infection. All patients presented non-severe classic dengue
fever without warning signs, bleeding disorders, or other
complications. Among hematological alterations, leukopenia was
a common ﬁnding in the four patients; this has been associated
with dengue infection in other studies.12
With regard to neurological status, no patient worsened, as
determined by the maintenance of EDSS scores. A variation in the
pattern of HTLV-1 PVL quantiﬁed before and after dengue fever
episodes was also not observed, as described in Table 1. The intra-
individual ﬂuctuation observed in the HTLV-1 PVL did not follow a
common tendency. Indeed, it was compatible with levels observed
during the normal clinical course of HTLV-1 infection, as described
by Demontis et al.14
Because of the small number of cases reported here, we do not
consider this a conclusive study. Nevertheless, despite the
expected mutual inﬂuence of DENV and HTLV-1 infections in
each virus-related disease, all patients presented classic dengue
fever and no worsening of HAM/TSP, suggesting that both diseases
present independent pathogenic mechanisms.
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